- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02709681
Hydroxyurea in the Treatment of Sickle Cell Disease
Hydroxyurea in Sickle Cell Disease: a Large Nation-wide Cohort Study From Italy
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The indication for hydroxyurea initiation was 2-3 vaso-occlusive crisis and/or hospitalizations in the last year.
The study will analyze demographics (age and gender), origin, genotype, clinical phenotype (vaso-occlusive or hemolytic), transfusion history (including exchange), and folic acid use, average laboratory values up to three years pre-hydroxyurea and for the period post-hydroxyurea therapy including total hemoglobin level, fetal hemoglobin level, hemoglobin S level, white blood count, platelet count, lactate dehydrogenase level, total and direct bilirubin levels, aspartate and alanine aminotransferase levels, and serum creatinine level.
The incidence of complications pre- and post-hydroxyurea therapy will be also analyzed including: stroke, silent cerebral infraction, acute chest syndrome, vaso-occlusive crisis, hospitalization, pulmonary hypertension, leg ulcers, bone necrosis, and kidney injury. Safety data included adverse events as reported by the treating physician and the incidence of malignancy or death as well as pregnancy incidents and their outcomes will be also pointed out.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Bari, Italien
- Azienda Ospedaliero-Universitaria
-
Brescia, Italien, 25100
- U.O. Oncoematologia Pediatrica Ospedali Civili
-
Brindisi, Italien, 72100
- Ospedale "A. Perrino"
-
Cagliari, Italien, 09121
- Azienda Ospedaliera Universitaria di Cagliari
-
Catania, Italien, 95123
- Ospedale Vittorio Emanuele
-
Catania, Italien, 95124
- ARNAS "Garibaldi"
-
Catania, Italien, 95124
- University of Catania
-
Catanzaro, Italien, 88100
- A.O. "Pugliese-Ciaccio"
-
Crotone, Italien
- Osp.San Giovanni Di Dio
-
Firenze, Italien, 50139
- Azienda Ospedaliero Universitaria Meyer
-
Genova, Italien, 16128
- E.O. Ospedali Galliera
-
Milano, Italien, 20122
- Universita Degli Studi Di Milano
-
Modena, Italien, 41124
- Azienda Ospedaliero-Universitaria di Modena - Policlinico
-
Monza, Italien, 20900
- Azienda Ospedaliera San Gerardo di Monza
-
Monza, Italien, 20052
- Clinica pediatrica Monza S. Gerardo
-
Napoli, Italien
- AORN A. Cardarelli
-
Padova, Italien, 35128
- Clinica di Onco-Ematologia Pediatrica, Università di Padova
-
Palermo, Italien, 90146
- Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
-
Palermo, Italien, 90100
- A.R.N.A.S. "Civico"
-
Parma, Italien, 43126
- Azienda Ospedaliero-Universitaria di Parma
-
Pavia, Italien, 27100
- Policlinico San Matteo
-
Ravenna, Italien, 48121
- Centro Emofilia e Medicina Trasfusionale - Pres. Ospedaliero
-
Reggio Calabria, Italien, 89100
- A. O. Bianchi Melacrino Morelli
-
Roma, Italien, 00144
- Ospedale S. Eugenio - FF UOSD DH Talassemici
-
Roma, Italien, 00168
- Università Cattolica del Sacro Cuore - Policlinico A.Gemelli
-
Siracusa, Italien, 96100
- U.O.S. Talassemia P.O. Umberto I°
-
Torino, Italien, 90146
- Università degli Suidi di Torino
-
Verona, Italien, 37122
- Policlinico G.B. Rossi
-
-
Agrigento
-
Sciacca, Agrigento, Italien, 92019
- Ospedali Civili Riuniti di Sciacca
-
-
Caltanisetta
-
Gela, Caltanisetta, Italien, 93012
- Ospedale Vittorio Emanuele III
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Sickle Cell Disease affected patients
- 2-3 vaso-occlusive crisis and/or hospitalizations in the last year
Exclusion Criteria
- none
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
SCD patients
Patients followed in 32 Italian Centers.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in laboratory parameters is being assessed
Tidsramme: An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy
|
Increases or decreases in percentage of total hemoglobin, fetal hemoglobin and hemoglobin S level will be assessed.
Changing of white blood cells and platelets counts, lactate dehydrogenase, bilirubin, aspartate aminotransferase and serum creatinine level will be also evaluated.
|
An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy
|
Changes in complication rates is being assessed
Tidsramme: An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy
|
Changing in the incidence of stroke, silent cerebral infraction, acute chest syndrome, vaso-occlusive crisis, pulmonary hypertension, leg ulcers, bone necrosis and kidney injury will be evaluated.
|
An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy
|
Rate of hospitalizations
Tidsramme: An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy
|
Changing in rate of hospitalizations before and after start hydroxyurea therapy
|
An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changing in the incidence of complications according to specific subgroups
Tidsramme: An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy
|
We also stratified the analysis according to age (≥18 years), origin (Italian and African), genotype (βS/β0, βS/β+ and βS/βS) duration of hydroxyurea treatment (≥10 years) and hydroxyurea dose(≥15 mg/kg/day).
|
An average of 3 years before and an average of 3 years after initiation of hydroxyurea therapy
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Paolo Rigano, MD, Servico Integrado de Tecnicas Endovasculares
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SocietaITE
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Seglcellesygdom
-
Universitaire Ziekenhuizen KU LeuvenUkendtLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
-
University of BolognaNovartisUkendtMyeloproliferative lidelser | Hypereosinofilt syndrom | Kronisk eosinofil leukæmi (CEL)Italien
-
AHS Cancer Control AlbertaCross Cancer InstituteAfsluttetOmfattende Stage Small Cel Lung CancerCanada
-
Novartis PharmaceuticalsAfsluttetKronisk myeloid leukæmi (CML) | Philadelphia kromosom positiv akut lymfoblastisk leukæmi (Ph+ ALL) | Andre Glivec/Gleevec-indicerede hæmatologiske lidelser (HES, CEL, MDS/MPN)Den Russiske Føderation
Kliniske forsøg med Physician standard-of-care in SCD patients
-
Universidade do PortoInstituto Portugues de Oncologia, Francisco Gentil, Porto; Unidade de Saúde... og andre samarbejdspartnereRekrutteringPapillomavirus infektioner | Livmoderhalskræft | Tidlig opdagelse af kræft | SelvundersøgelsePortugal
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)AfsluttetDiabetes mellitus, type 1Forenede Stater